Swiss biotech Neurimmune has sold part of its future royalties from its AstraZeneca-partnered experimental heart drug cliramitug to Royalty Pharma for up to $425 million, giving it fresh cash to invest in its remaining antibody pipeline.
Tag Archive for: licensing
AstraZeneca has agreed to pay up to $1.5bn for global rights to Zegfrovy, an EGFR-targeted lung cancer drug developed by Dizal Pharmaceutical – the Chinese biotech it helped create nearly a decade ago.
GSK has pulled out of its neuroscience collaboration with Alector, ending a 2021 alliance that began with a $700m upfront payment but has since been hit by two clinical setbacks.
AstraZeneca has moved to strengthen its respiratory pipeline with a late-stage Chinese COPD asset, striking a deal that gives it a lower-cost shot at a market MSD recently entered through its $10bn Verona Pharma acquisition.
Boehringer Ingelheim has licensed oncology rights to Prime Vector Technologies’ (PVT) Orf virus platform to develop a new generation of cancer vaccines.
Roche’s Genentech has signed an oncology research deal with Astex, hoping the UK-based biotech will hit the jackpot again after a similar tie-up with rival Novartis produced the blockbuster breast cancer drug Kisqali.
AstraZeneca has signed another deal with China’s CSPC Pharmaceutical Group, this time to discover and develop siRNA drug candidates for kidney diseases.
Swedish biotech AlzeCure Pharma has licensed global rights to its NeuroRestore platform, including lead Alzheimer’s candidate ACD856, to Danish biotech QuantumCell ApS in a deal worth more than $2.2bn, excluding royalties.
Italian pharma Recordati has entered into a license agreement with Ionis Pharmaceuticals, Inc. for exclusive development and marketing rights to zilganersen, an investigational RNA-targeted medicine for the treatment of Alexander disease (AxD), in all countries outside the U.S.
Novartis has signed a multi-target oncology discovery deal with Antares Therapeutics, paying $105m upfront for access to the Boston biotech’s small-molecule discovery engine. The agreement could bring Antares up to $1.8bn more in option, development, regulatory and commercial milestones, plus tiered royalties on global net sales that could reach the low double-digit range.